WALTHAM, MA--(Marketwired - November 03, 2014) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of five new books within the pharmaceutical sciences reflecting the latest in research and development, including the fourth edition of A Pharmacology Primer: Techniques for More Effective and Strategic Drug Discovery, authored by world-renowned pharmacologist, Terry Kenakin, PhD. These books and others in Elsevier's pharmaceutical sciences portfolio will be on display in the Elsevier booth # 2541 at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, November 2-6 in San Diego, CA.
- Read more about A Pharmacology Primer and author Terry Kenakin here
There have been several major developments in drug discovery over the past years, including advances in structure-based drug design and the realization that drugs do not uniformly activate receptors but rather are biased toward signaling pathways. The revised edition of A Pharmacology Primer equips researchers with the latest research, methods and approaches used for lead optimization in order to further successful drug discovery. Important new topics include in silico analysis of chemical libraries, signaling bias for much improved target selection, and data-driven drug discovery.
Dr. Kenakin is a professor in the Pharmacology Department at University of North Carolina School of Medicine and the recipient of the 2014 Gaddum Memorial Award from the British Pharmacological Society. In addition, he is a member of numerous journal editorial boards as well as Editor-in-Chief of the Journal of Receptors and Signal Transduction and Elsevier's Current Opinion in Pharmacology.
The new pharmaceutical books are:
- A Pharmacology Primer: Techniques for More Effective and Strategic Drug Discovery, Fourth Edition by Terry Kenakin
- Design and Manufacture of Pharmaceutical Tablets by Reynir Eyjolfsson
- Drug Stability for Pharmaceutical Scientists by Thorsteinn Loftsson
- The Organic Chemistry of Drug Design and Drug Action by Richard Silverman and Mark W. Holladay
- Biased Signaling in Physiology, Pharmacology and Therapeutics by Brian Arey
The books are available on the Elsevier Store and on ScienceDirect, Elsevier's full-text scientific database offering journal articles and book chapters from over 2,200 peer-reviewed journals and more than 25,000 book titles.
Elsevier book editor, Anthony Atala, MD, a practicing surgeon and researcher in regenerative medicine, will also be presenting a keynote at the AAPS meeting: "Organ Printing," during the Plenary Session on November 3 at 10:00 am PST. His work was listed by Smithsonian in 2010 as one of "40 Things to Know About the Next 40 years" and by Time in 2011 as one of the top five medical breakthroughs of the year. He is the editor of twelve books, including Principles of Regenerative Medicine and Foundations of Regenerative Medicine. Dr. Atala has published more than 400 journal articles and has applied for or received over 200 national and international patents.
Notes for Editors
Review copies of the books are available to credentialed journalists upon request. Contact Michelle McMahon at m.mcmahon.1@elsevier.com or +1 781 663 2268.
About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey -- and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are: (
Image Available: http://www.marketwire.com/library/MwGo/2014/10/31/11G025162/Images/A_Pharmacology_Primer_Ch1_Fig3_potential_drug_targ-444404067834.jpg
Image Available: http://www.marketwire.com/library/MwGo/2014/10/31/11G025162/Images/A_Pharmacology_Primer_Ch11_Fig3_druggable_genomes-1273513130630.jpg
Image Available: http://www.marketwire.com/library/MwGo/2014/10/31/11G025162/Images/A_Pharmacology_Primer_hi-res-822105669500.jpg
Contact Information:
Media contact
Michelle McMahon
Publicity Manager, Science & Technology Books
Elsevier
+1 781 663 2268
m.mcmahon.1@elsevier.com
